Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: Discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range

Journal of Medicinal Chemistry

Volumn 42, Issue 10, 1999, Pages 1687-1697

  Teodori, Elisabetta ^a   Dei, Silvia ^a   Quidu, Patricia ^c   Budriesi, Roberta ^b   Chiarini, Alberto ^b   Garnier Suillerot, Arlette ^c   Gualtieri, Fulvio ^a   Manetti, Dina ^a   Romanelli, Maria Novella ^a   Scapecchi, Serena ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MM 36; PIRARUBICIN; UNCLASSIFIED DRUG; VERAPAMIL DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CELL STRAIN K 562; CHEMOSENSITIVITY; CHRONOTROPISM; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; INOTROPISM; MULTIDRUG RESISTANCE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANISOLES; ANTINEOPLASTIC AGENTS; AORTA; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HEART RATE; HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRILES; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033587112     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980440p     Document Type: Article

References (67)

1. Lacombe, P. S.; Vicente, J. A. G.; Pagès, J. G.; Morselli, P. L. Causes and problems of non response or poor response to drugs. Drugs 1996, 51, 552-570.
2. Simon, S. M.; Schindler, M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3497-3504.
3. Bosch, I.; Croop, J. P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta 1998, 1288, F37-F54.
4. Kane, S. E. Multidrug resistance of cancer cells; Kane, S. E., Ed.; Academic Press: 1996; Vol. 24, pp 181-252.
5. Moscow, J. A.; Schneider, E.; Cowan, K. H. Multidrug resistance in cancer chemotherapy and biological response modifiers annual; Elsevier Science B.V.: Amsterdam, 1996; Vol. 16.
6. Bourhis, J.; Riou, G.; Bénard, J. Expression de la p-glycoproteine 170 (GP170) et résistance à la chimiothérapie de cancers humains. Bull. Cancer 1990, 77, 957-965.
7. Nooter, K.; Stoter, G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Path. Res. Pract. 1996, 192, 768-780.
8. Muller, M.; de Vries, E. G. E.; Jansen, P. L. M. Role of multidrug resistance protein (MRP) in glutathione S-coniugate transport in mammalian cells. J. Hepatol. 1996, 24 (Suppl. 1), 100-108.
9. Bolhuis, H.; van Veen, E. W.; Poolman, B.; Driessen, A. J. M.; Konings, W. N. Mechanisms of multidrug transporters. FEMS Microbiol. Rev. 1997, 21, 55-84.
10. Jenkinson, H. F. Ins and out of antimicrobial resistance: era of the drug pumps. J. Dental Res. 1996, 75, 736-742.
11. van Veen, H. W.; Konings, W. N. Drug efflux proteins in multidrug resistance bacteria. Biol. Chem. 1997, 376, 769-777.
12. Meijer, D. K. F.; Smit, I. W.; Muller, M. Hepatobiliary elimination of cationic drugs: the role of p-glycoprotein and other ATP-dependent transporters. Adv. Drug Deliv. Rev. 1997, 25, 159-200.
13. Hunter, J.; Hirst, B. H. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv. Drug Deliv. Rev. 1997, 25, 129-157.
14. van Asperen, J.; Mayer, U.; van Tellingen, O.; Beijnen, J. H. The functional role of P-glycoprotein in the blood-brain barrier. Pharmacol. Sci. 1997, 86, 881-884.
15. Fan, D.; Beltran, P. J.; O'Brian, C. A. In Reversal of multidrug resistance; Fan, D., Beltran, P. J., O'Brian, C. A., Eds.; CRC Press: Boca Raton, FL, 1994; pp 93-125.
16. Gualtieri, F. Drugs reverting Multidrug resistance (Chemosensitizers). Chim. Industria 1996, 78, 1233.
17. Ford, J. M. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur. J. Cancer 1996, 32A, 991-1001.
18. Robert, J. Multidrug resistance reversal agents. Drug Future 1997, 22, 149-158.
19. Raderer, M.; Scheithauer, W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993, 72, 3553-3563.
20. Robert, J. La multidrug resistance aux médicaments anticancéreux. Bull. Cancer 1994, 9 (Suppl. 1), 33s-38s.
21. Ecker, G.; Chiba, P. Recent developments in overcoming tumor cell multi-drug resistance. Exp. Opin. Ther. Patents 1897, 7, 589-599.
22. Pommerenke, E. W.; Osswald, H.; Hahn, E. W.; Volm, M. Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells. Cancer Lett. 1990, 55, 17-23.
23. Klopman, G.; Srivastava, S.; Kolossvary, I.; Epand, R. F.; Ahmed, N.; Epand, R. M. Structure-activity study and design of multidrug resistance reversal compounds by a computer automated structure evaluation methodology. Cancer Res. 1992, 52, 4121-4129.
24. Ramu, A.; Ramu, N. Reversal of multidrug resistance by bis-(phenylalkyl)amines and structurally related compounds. Cancer Chemother. Pharmacol. 1994, 34, 423-430.
25. Klopman, G.; Shi, L. M.; Ramu, A. Quantitative structure-activity relationship of multidrug reversal agents. Mol. Pharmacol. 1997, 52, 323-334.
26. Zamora, M.; Pearce, H. L.; Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol. 1988, 33, 454-462.
27. Pearce, H. L.; Winter, M. A.; Beck, T. V. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance. Adv. Enzyme Regul. 1990, 30, 357-373.
28. Ueda, K.; Taguchi, Y.; Morishima, M. How does P-glycoprotein recognize its substrates? Cancer Biol. 1997, 8, 151-159.
29. Pereira, E.; Teodori, E.; Dei, S.; Gualtieri, F.; Garnier-Suillerot, A. Reversal of multidrug resistance by verapamil analogues. Biochem. Pharmacol. 1995, 50, 451-457.
30. Litman, T.; Zeuthen, T.; Skovssgard, T.; Stein, W. D. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATP-ase activity. Biochim. Biophys. Acta-Mol. Bases Disease 1997, 1361, 159-168.
31. Matsumoto, T.; Fujii, R.; Sugita, M.; Sumizawa, T.; Sakai, S.; Takahashi, T.; Sueda, N.; Furukawa, T.; Akiyama, S.; Nagata, Y. Effect of newly synthesized indole derivatives on multidrug resistance in human cancer cells. Anti-Cancer Drug Des. 1994, 9, 251-261.
32. Chiba, P.; Ecker, G.; Schmid, D.; Drach, J.; Tell, B.; Goldemberg, S.; Gekeler, V. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance. Mol. Pharmacol. 1996, 49, 1122-1130.
33. Chiba, P.; Tell, B.; Jager, W.; Richter, E.; Hitzler, M.; Ecker, G. Studies on propaphenone-type modulators of multidrug-resistance IV: synthesis and pharmacological activity of 5-hydroxy and 5-benzyloxy derivatives. Arch. Pharmacol. 1997, 330, 343-347.
34. Eliason, J. F.; Ramuz, H.; Yoshikubo, T.; Ishikawa, T.; Yamamoto, T.; Tsuruo, T. Novel dithiane analogues of thiapamil with high activity to overcome multidrug resistance in vitro. Biochem. Pharmacol. 1995, 50, 187-196.
35. De Jong, G.; Gelmon, K.; Bally, M.; Goldie, J.; Mayer, L. Modulation of doxorubicin resistance in P388/ADR cells by Ro 44-5912, a tiapamil derivative. Anticancer Res. 1995, 15, 911-916.
36. Toffoli, G.; Simone, F.; Corona, G.; Raschack, M.; Cappelletto, B.; Gigante, M.; Boiocchi, M. Structure-activity relationships of verapamil analogues and reversal of multidrug resistance. Biochem. Pharmacol. 1995, 50, 1245-1255.
37. Pawagi, A. B.; Wang, J.; Silverman, M.; Reithmeier, R. A. F.; Deber, C. M. Transmembrane aromatic amino acid distribution in p-glycoprotein: a functional role in broad substrate specificity. J. Mol. Biol. 1994, 235, 554-564.
38. Quesada, A. R.; Garcia Gravalos, M. D.; Fernandez Puentes, J. L. Poliaromatic alkaloids from marine invertebrates as cytotoxic compounds and inhibitors of multidrug resistance caused by P-glycoprotein. Br. J. Cancer 1996, 74, 677-682.
39. Dhainaut, A.; Régnier, G.; Atassi, G.; Pierré, A.; Leonce, S.; Kraus-Berthier, L.; Prost, J.-F. New triazine derivatives as potent modulators of multidrug resistance. J. Med. Chem. 1992, 35, 2481-2496.
40. Kulp, S. S.; Fish, V. B.; Easton, N. R. Some reactions and derivatives of 2,2-diphenylcyclopentanone. J. Med. Chem. 1963, 6, 516-519.
41. Dengel, F. Substituted phenylacetonitriles. Knol A.-G. Chemische Fabriken: Brit.1,192,625; (Chem. Abstr. 1970, 73,45182n.
42. Teodori, E.; Dei, S.; Romanelli, M. N.; Scapecchi, S.; Gualtieri, F.; Budriesi, R.; Chiarini, A.; Lemoine, H.; Mannhold, R. Synthesis and pharmacological evaluation of verapamil analogues with restricted molecular flexibility. Eur. J. Med. Chem. 1994, 29, 139-148.
43. Zajac, W. W.; Siuda, J. F.; Nolan, M. J.; Santosusso, T. M. Reaction of nitriles with hydrazine and Raney nickel. J. Org. Chem. 1971, 36, 3539-3541.
44. Aldrich, P. E.; Hermann, E. C.; Meier, W. E.; Paulshock, M.; Prichard, W. W.; Snyder, J. A.; Watts, J. C. Antiviral agents. 2. Structure-activity relationships of compounds related to 1-adamantanamine. J. Med. Chem. 1971, 14, 535-543.
45. Wiesmann, F.; Rademacher, P. Spectroscopic investigations of bicyclic amino ketones. Chem. Ber. 1994, 127, 1517-1522.
46. Hoyng, C. F.; Patel, A. D. A base-labile amine component in four-component condensation (4CC) synthesis. J. Chem. Soc., Chem. Commun. 1981, 491-492.
47. Monro, A. M.; Quinton, R. M.; Wrigley, T. I. Some analogues of imipramine. J. Med. Chem. 1963, 6, 255-261.
48. Kumar, C. V.; Tolosa, L. M. Interaction of hydrophobic probes with serum albumin- Influence of the side chain and exciplex formation at the binding site. J. Phys. Chem. 1993, 97, 13914-13919.
49. Dahn, H.; Solms, U. Uber eine umlagerung tertiarer amine durch lithiumaluminiumhydrid. Helv. Chim. Acta 1951, 34, 907-915.
50. Hollt, V.; Kouba, M.; Dietel, M.; Vogt, G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem. Pharmacol, 1992, 43, 2601-2608.
51. Frézard, F.; Garnier-Suillerot, A. Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and -sensitive K562 cells. Biochim. Biophys. Acta 1991, 1091, 29-35.
52. Frézard, F.; Garnier-Suillerot, A. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur. J. Biochem. 1991, 196, 483-491.
53. Pereira, E.; Borrel, M.-N.; Fiallo, M.; Garnier-Suillerot, A. Noncompetitive inhibition of P-glycoprotein-associated efflux of THP-adriamicin by verapamil in living K562 leukemia cells. Biochim. Biophys. Acta 1994, 1225, 209-216.
54. Pereira, E.; Garnier-Suillerot, A. Correlation between the short-term measurements of drug accumulation in living cells and the long-term growth inhibition. Biochem. Pharmacol. 1994, 47, 1851-1857.
55. Mankhetkorn, S.; Dubru, F.; Hesschenbrouck, J.; Fiallo, M.; Garnier-Suillerot, A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubidn, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol. Pharmacol. 1996, 49, 532-539.
56. Bellucci, C.; Gualtieri, F.; Scapecchi, S.; Teodori, E.; Budriesi, R.; Chiarini, A. Negative Inotropic and Calcium Antagonistic Activity of Alkyl and Arylalkyl Phosphonates. Farmaco 1989, 44, 1167-1191.
57. Sikic, B. I. Pharmacologic approaches to reversing multidrug resistance. Semin. Hematol. 1997, 34 (suppl. 5), 40-47.
58. den Ouden, D.; van den Heuvel, M.; Schoester, M.; van Rens, G.; Sonneveld, P. In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. Leukemia 1996, 10, 1930-1936.
59. Ojima, I.; Bounaud, P.-Y.; Takeuchi, C.; Pera, P.; Bernacki, R. J. New taxanes as highly efficient reversal agents for multi-drug resistance in cancer cells. Bioorg. Med. Chem. Lett. 1998, 8, 189-194.
60. Bain, L. J.; McLachlan, J. B.; LeBlanc, G. A. Structure-activity relationships for xenobiotic transport substrates and inhibitory ligands of P-glycoprotein. Environ. Health Perspect. 1997, 105, 812-818.
61. Litman, T.; Zeuthen, T.; Skovsgaard, T.; Stein, W. D. Competitive, noncompetitive and cooperative interactions between substrates of p-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta 1997, 1361, 169-176.
62. Pajeva, I.; Wiese, M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J. Med. Chem. 1998, 41, 1815-1826.
63. 2+-antagonistic activities of α-alkyl-α-((phenoxypropylamino)propyl)benzeneacetonitrile derivatives. Chem. Pharm. Bull. 1988, 36, 373-385.
64. Lozio, C. B.; Lozio, B. B. Human chronic myelogenous leukemia cell line positive philadelphia chromosome. Blood 1975, 45, 321-334.
65. Tsuruo, T.; Iida, H.; Kawataba, H.; Oh-hara, T.; Hamada, H.; Utakoji, T. Characteristics of resistance to adriamicin in human myelogenous leukemia K 562 resistant to adriamicin and in isolated clones. Jpn. J. Cancer Res. 1986, 46, 682-687.
66. Mankhetkorn, S.; Garnier-Suillerot, A. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. Eur. J. Pharmacol. 1998, 343, 313-321.
67. Tallarida, R. J.; Murray, R. B. Manual of pharmacological calculations with computer programs; Springer-Verlag: New York, 1991; Version 2, pp 153-159.